Search results for "agonists"

showing 10 items of 1616 documents

Sources of human plasma cyclic AMP. Examinations before and after beta 2 adrenergic stimulation.

1981

Plasma cyclic AMP was measured in different vessels in seventeen volunteers before and after stimulation with terbutaline. Differences between arterial blood and blood from the hepatic vein, right ventricle, inferior vena cava and a cubital vein could not be demonstrated. Only in the renal vein was the concentration of cyclic AMP decreased. Our results indicate that cyclic AMP is not generated from any specific isolated organ and that changes in cyclic AMP after subcutaneous injection of terbutaline reflect a general influence of this drug.

AdultMalemedicine.medical_specialtyInjections SubcutaneousTerbutalineStimulation030204 cardiovascular system & hematology030226 pharmacology & pharmacyBiochemistryInferior vena cava03 medical and health sciences0302 clinical medicineAdrenergic stimulationInternal medicineCyclic AMPTerbutalineMedicineHumansVeinAgedbusiness.industryBiochemistry (medical)Cell BiologyGeneral MedicineAdrenergic beta-AgonistsMiddle AgedStimulation Chemicalmedicine.anatomical_structureEndocrinologymedicine.veinVentriclecardiovascular systemArterial bloodRenal veinbusinessmedicine.drugThe Journal of international medical research
researchProduct

Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week

2009

<i>Background:</i> Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) is characterized by recurrent edema attacks in various organs. The objective of the present study was to assess the efficacy and safety of weekly long-term replacement treatment with one or more injections of plasma-derived C1-INH concentrate per week (WLTC) in patients with HAE-C1-INH. <i>Methods:</i> Nineteen patients with HAE-C1-INH underwent WLTC for 9 years on average. The benefits and risks were determined based on regular recording by the patients of the severity and number of attacks at the beginning and the end of the study. <i>Results:</i> All patients reported …

AdultMalemedicine.medical_specialtyLong term treatmentC1 inhibitor deficiencyImmunologyBradykininGastroenterologyDrug Administration ScheduleC1-inhibitorEdemaInternal medicineHumansImmunology and AllergyMedicineProspective Studiesskin and connective tissue diseasesBradykinin Receptor AntagonistsC1 esterase inhibitor deficiencyAgedbiologyAngioedemabusiness.industryAngioedemas HereditaryGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseSurgeryHereditary angioedemaImmunologybiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinInternational Archives of Allergy and Immunology
researchProduct

Stratified Care vs Step Care Strategies for Migraine

2000

ContextVarious guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.ObjectiveTo compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.Design and SettingRandomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical cen…

AdultMalemedicine.medical_specialtyMetoclopramideMigraine DisordersPopulationZolmitriptanSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessHumansMedicineeducationOxazolidinonesAspirineducation.field_of_studyAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialMigraineCritical PathwaysPhysical therapyDopamine AntagonistsFemalebusinessmedicine.drugJAMA
researchProduct

Relaxation by β3-adrenoceptor agonists of the isolated human internal anal sphincter

2009

In this study, responses of beta(3)-adrenoceptor agonists were examined on human isolated internal anal sphincter (IAS) in order to explore their relaxant effects on hypertonicity of IAS.The relaxant efficacy (E(max)) and potency (-logIC(50)) of BRL37344 and SR58611A, beta(3)-adrenoceptor agonists, were examined in contracted IAS muscle strips. The presence of beta(3)-adrenoceptors, and changes in intracellular calcium and cyclic nucleotide levels in IAS muscle were tested by Western blotting, epifluorescence microscopy and enzyme immunoassay, respectively.BRL37344 and SR58611A relaxed contracted IAS muscle (E(max)=27+/-3% and 35+/-3%; -logIC(50)=6.26+/-0.24 and 4.87+/-0.13; respectively). …

AdultMalemedicine.medical_specialtyMuscle RelaxationAnal CanalAdrenergic beta-3 Receptor AgonistsIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyCalcium in biologyInternal anal sphincterInternal medicinemedicineHumansPotencyGeneral Pharmacology Toxicology and PharmaceuticsAgedAged 80 and overDose-Response Relationship DrugRelaxation (psychology)Sphincter tonebusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle AgedEndocrinologyEthanolaminesReceptors Adrenergic beta-3Femaleβ3 adrenoceptorbusinessLife Sciences
researchProduct

Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension

2002

The objective of the study was to assess the factors related to the occurrence of microalbuminuria during the follow-up of a young adult group with essential hypertension that had not been previously treated. Normo-albuminuric essential hypertensives, <50 years old, who had not been previously treated with antihypertensive drugs and who did not have diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=62), β-blockers (n=38), ACE inhibitors (n=64), calcium channel blockers (n=8), and several classes (n=15). Measurements were taken for office blood pressure, biochemical profile, and 24-hour urinary albumin excretion…

AdultMalemedicine.medical_specialtyNifedipineAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsEssential hypertensionEnalaprilLisinoprilRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaBisoprololHumansYoung adultAntihypertensive AgentsProportional Hazards ModelsProteinuriabusiness.industryFollow up studiesMiddle AgedCalcium Channel Blockersmedicine.diseaseTreatment OutcomeEndocrinologyBlood pressureAtenololHypertensionAlbuminuriaRegression AnalysisFemaleMicroalbuminuriamedicine.symptombusinessPreviously treatedHypertension
researchProduct

Multiple Peptide Hormone Producing Adenocarcinoma of Lung with Neurotensin and CRF-like Immunoreactivity

1988

Summary A pulmonary cancer of a 43 year-old-man was classified according to WHO-criteria as a poorly differentiated adenocarcinoma because of demonstration of mucinous substances in tumor cells and in rarely occurring acinar lumina. Immunohistochemical reactivity for several peptide hormones was detected in the predominant solid parts of the carcinoma. In many tumor cells an immunoreactivity to neurotensin, bombesin and — according to the elevated serum levels — to ACTH, CRF and calcitonin was found. Therefore the present lung cancer must be defined as a combined carcinoma composed of mucous producing and endocrine cell types. Because peptide hormone production is not restricted to the clas…

AdultMalemedicine.medical_specialtyPathologyLung NeoplasmsCorticotropin-Releasing HormoneEnteroendocrine cellAdenocarcinomaPeptide hormoneBiologyPathology and Forensic Medicinechemistry.chemical_compoundInternal medicinemedicineCarcinomaHumansLung cancerNeurotensinBombesinCell Biologymedicine.diseaseImmunohistochemistryEndocrinologychemistryCalcitoninHormones EctopicAdenocarcinomahormones hormone substitutes and hormone antagonistsNeurotensinPathology - Research and Practice
researchProduct

Controversies and challenges in the management of chronic urticaria

2016

This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Despite the clear international guideline, there remain a number of controversies and challenges in the management of patients with chronic urticaria (CU). As a result of major advancements in urticaria over the past 4 years, the current EAACI/GA(2) LEN/EDF/WAO urticaria guideline treatment algorithm requires updating. Case studies from patients with chronic spontaneous urticaria (CSU) [also called chronic idiopathic urticaria (CIU)], chronic inducible urticaria (CIndU) or diseases and syndromes related to CU are useful in describing and exploring chall…

AdultMalemedicine.medical_specialtyPathologyUrticariaAlternative medicineDermatologyUnmet needs030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseasesparasitic diseasesmedicineHumansAngioedemaDisease management (health)ChildIntensive care medicineskin and connective tissue diseasesChronic urticariaAgedbusiness.industryGuidelineMiddle AgedPedigreeCold TemperatureInfectious Diseases030228 respiratory systemChronic DiseaseHistamine H1 AntagonistsSunlightFemaleChronic idiopathic urticariabusiness
researchProduct

Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study.

2006

The objective of the present study was to assess factors related to long-term changes in urinary albumin excretion (UAE) of nondiabetic microalbuminuric (n = 252) or proteinuric hypertensive individuals (n = 58) in a prospective follow-up.After enrollment, patients were placed on usual care including nonpharmacological treatment and/or treatment with an antihypertensive drug regime to achieve blood pressure135/85 mmHg. Periodic UAE measurements were performed until regression or significant reduction (defined when UAE dropped50% from the initial values, plus reduction of UAE to30 mg/24 h for microalbuminuric patients and300 mg/24 h for proteinuric patients).Among the microalbuminuric patien…

AdultMalemedicine.medical_specialtyPhysiologymedicine.drug_classAdrenergic beta-AntagonistsUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive drugbusiness.industryProportional hazards modelHazard ratioMiddle Agedmedicine.diseaseCalcium Channel BlockersConfidence intervalEndocrinologyBlood pressureHypertensionFemaleCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor BlockersFollow-Up StudiesGlomerular Filtration RateJournal of hypertension
researchProduct

Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT

1996

By the application of 123([123I]IBZM), an iodine-labelled dopamine D2-receptor antagonist, brain D2 receptors in humans can be visualized with single photon emission computed tomography (SPECT). The ratio of IBZM binding to striatal regions versus binding to frontal cortex (ST/FC ratio) provided a semiquantitative measurement of D2 receptor binding in the striatum. This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Prolactin levels were positively correlated with D2 receptor occupancy, reflecting at least in part a comparable dopamine receptor antagonism in different dopaminer…

AdultMalemedicine.medical_specialtyPyrrolidinesStriatumIodine RadioisotopesBenperidolProsencephalonDopamineDopamine receptor D2Internal medicinemedicineHumansReceptorClozapineTomography Emission-Computed Single-PhotonPharmacologySchizophrenia ParanoidReceptors Dopamine D2ChemistryBenperidolMiddle AgedCorpus StriatumProlactinProlactinEndocrinologymedicine.anatomical_structureDopamine receptorDopaminergic pathwaysBenzamidesDopamine AntagonistsHaloperidolAntipsychotic Agentsmedicine.drugPsychopharmacology
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct